3,584 Shares in Masimo Co. (NASDAQ:MASI) Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. bought a new stake in shares of Masimo Co. (NASDAQ:MASI) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 3,584 shares of the medical equipment provider’s stock, valued at approximately $478,000.

Other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its holdings in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC boosted its stake in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC raised its position in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 573 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 1.7 %

Masimo stock opened at $163.50 on Wednesday. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $173.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market capitalization of $8.75 billion, a PE ratio of 112.76 and a beta of 0.97. The firm has a 50 day simple moving average of $139.17 and a 200-day simple moving average of $127.02.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.63 EPS. As a group, equities research analysts expect that Masimo Co. will post 4.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a research report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler upped their target price on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Wells Fargo & Company lifted their price target on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $163.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.